Halozyme
HALO
618 hedge funds and large institutions have $8.29B invested in Halozyme in 2025 Q4 according to their latest regulatory filings, with 108 funds opening new positions, 219 increasing their positions, 222 reducing their positions, and 82 closing their positions.
165% more call options, than puts
Call options by funds: $45.5M | Put options by funds: $17.2M
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
32% more first-time investments, than exits
New positions opened: 108 | Existing positions closed: 82
2.8% more ownership
Funds ownership: 101.97% → 104.77% (+2.8%)
2% more funds holding
Funds holding: 603 → 618 (+15)
1% less repeat investments, than reductions
Existing positions increased: 219 | Existing positions reduced: 222
5% less capital invested
Capital invested by funds: $8.75B → $8.29B (-$458M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
+$124M |
| 2 |
MMA
Mizuho Markets Americas
New York
|
+$62.3M |
| 3 |
Morgan Stanley
New York
|
+$61.9M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$55.1M |
| 5 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$51.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$113M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$106M |
| 3 |
D.E. Shaw & Co
New York
|
-$67.3M |
| 4 |
Jane Street
New York
|
-$61.3M |
| 5 |
Two Sigma Investments
New York
|
-$40.3M |
HALO Hedge Fund Activity: Q4 2025 in Review
618 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q4 2025, worth a combined $8.29B — down 5.2% from $8.75B a quarter earlier.
Buyers outnumbered sellers: 108 funds opened new HALO positions and 82 closed out — a net gain of 26 holders — while 219 added to existing stakes and 222 trimmed.
The largest buyer was William Blair Investment Management, opening a new position worth an estimated $124M. The largest seller was Macquarie Group, exiting entirely with an estimated $113M sold.
- 618 institutional investors held Halozyme (HALO) as of Q4 2025, up from 603 in Q3 2025.
- Funds reported $8.29B of Halozyme stock for Q4 2025, down 5.2% quarter-over-quarter.
- 108 funds opened new Halozyme positions in Q4 2025 and 82 closed out, a net change of +26 holders.
- The largest Halozyme buyer in Q4 2025 was William Blair Investment Management, an estimated $124M added.
- The largest Halozyme seller in Q4 2025 was Macquarie Group, an estimated $113M sold.
Based on aggregated 13F filings for Q4 2025.